Dominic Jack (D Jack)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Combination Therapy

Magnetic Resonance

Multiple Sclerosis

Top Venues

Journal of neurology

European journal of neurology

Patient preference and adherence

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Hugo Vrenken, Marco Battaglini, M L de Vos, G J Nagtegaal, Bernardo Corrêa de Almeida Teixeira, Andrea Seitzinger, Dominic Jack, Maria Pia Sormani, Bernard M J Uitdehaag, A Versteeg, Giancarlo Comi, Ludwig Kappos, Nicola De Stefano, Frederik Barkhof
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a. Journal of neurology 270 (4) (2023)
Hugo Vrenken, Marco Battaglini, M L de Vos, G J Nagtegaal, Bernardo Corrêa de Almeida Teixeira, Andrea Seitzinger, Dominic Jack, Maria Pia Sormani, Bernard M J Uitdehaag, A Versteeg, Giancarlo Comi, Ludwig Kappos, Nicola De Stefano, Frederik Barkhof
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a. Journal of neurology 270 (4) (2023)
Hugo Vrenken, Marco Battaglini, M L de Vos, G J Nagtegaal, Bernardo Corrêa de Almeida Teixeira, Andrea Seitzinger, Dominic Jack, Maria Pia Sormani, Bernard M J Uitdehaag, A Versteeg, Giancarlo Comi, Ludwig Kappos, Nicola De Stefano, Frederik Barkhof
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a. Journal of neurology 270 (4) (2023)
Yu-Ting Lin, Tamara Will, Charlotte Wickham, Petra Boeree, Dominic Jack, Matthew Keiser
Evolution of the RebiSmart ® Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis. Patient preference and adherence 17 (2023)
Hugo Vrenken, Marco Battaglini, M L de Vos, G J Nagtegaal, Bernardo Corrêa de Almeida Teixeira, Andrea Seitzinger, Dominic Jack, Maria Pia Sormani, Bernard M J Uitdehaag, A Versteeg, Giancarlo Comi, Ludwig Kappos, Nicola De Stefano, Frederik Barkhof
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a. Journal of neurology 270 (4) (2023)
Francesco Piras, Lilian Arnaud, Eric Henninger, Matthew Keiser, Andrea Seitzinger, Dominic Jack, Quentin Le Masne
Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years. Expert opinion on drug delivery (2023)
Hugo Vrenken, Marco Battaglini, M L de Vos, G J Nagtegaal, Bernardo Corrêa de Almeida Teixeira, Andrea Seitzinger, Dominic Jack, Maria Pia Sormani, Bernard M J Uitdehaag, A Versteeg, Giancarlo Comi, Ludwig Kappos, Nicola De Stefano, Frederik Barkhof
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a. Journal of neurology (2023)
Marco Battaglini, Hugo Vrenken, Riccardo Tappa Brocci, Giordano Gentile, Ludovico Luchetti, Adriaan Versteeg, Mark S Freedman, Bernard M J Uitdehaag, Ludwig Kappos, Giancarlo Comi, Andrea Seitzinger, Dominic Jack, Maria Pia Sormani, Frederik Barkhof, Nicola De Stefano
Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a. European journal of neurology 29 (7) (2022)
Gavin Giovannoni, Giancarlo Comi, Kottil Rammohan, Peter Rieckmann, Fernando Dangond, Birgit Keller, Dominic Jack, Patrick Vermersch
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. Advances in therapy 38 (9) (2021)